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ABSTRACT 
Objective: This study was conducted to develop a sensitive and effective LC-MS/MS method for the determination of bencycloquidium bromide 
(BCQB) and its application in pharmacokinetic drug interaction study between BCQB and paroxetine. 
Methods: The chromatographic separation was performed on Hedera ODS-2 C18 column with a mobile phase consisted of acetonitrile-10 mmol/l 
ammonium acetate containing 0.2% acetic acid (33:67, v/v) at 550 μl/min, and the plasma samples were processed using solid-phase extraction. 
The MS/MS transitions were m/z 330.2 → 142.0 for BCQB and m/z 344.2 → 156.1 for the I. S in positive ESI mode. 
Results: The validated method was linear over the concentration range of 2-1200 pg/ml with the correlation coefficient r2>0.998. The intra-and 
inter-batch precisions of the assay were lower than 8.2% and 9.1%, respectively. The lower limit of quantification (LLOQ) was 2 pg/ml. The stability 
data at different storage conditions of BCQB were within±5% RE. The mean AUC0-36 of BCQB was increased by approximately 33%, after the 
administration of BCQB alone and upon co-administration with paroxetine during the drug interaction study. 
Conclusion: The LC-MS/MS method validated in this study was robust, reproducible, accurate, precise and reliable and was successfully applied in 
the pharmacokinetic drug interaction studies.  
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INTRODUCTION 
Bencycloquidium bromide (BCQB) is a selective muscarinic M1/M3 
receptor antagonist developed for the treatment of rhinitis, asthma and 
chronic obstructive pulmonary disease (COPD) [1-3]. Studies on general 
pharmacological actions of BCQB suggested that it had no obvious effect 
on cardiovascular and respiratory in beagle dogs, and could decrease the 
extraction of the bronchus gland and inhibit the peristalsis of the small 
intestine in mice [4, 5]. Under the clinical trial, an early study has shown 
its tolerability and efficacy [6]. However, the investigations of drug 
interactions of BCQB in humans remain an important part of its safety. 
Our recent study on in vitro metabolism and disposition of BCQB in 
human revealed that BCQB is the substrate of several metabolic 
enzymes. It is metabolized mainly by CYP2D6 and also weekly by 
CYP3A4/5 and CYP2C19 [7-8]. During BCQB drug development phase, it 
is required to perform pharmacokinetic drug interaction studies with 
other drugs (known as inhibitors or inducer of metabolic enzymes) 
based on blood concentration measurements. Most often, plasma is 
prepared and used for analytical investigation in such studies [9-10]. A 
number of bioanalytical methods have been described for the 
determination of BCQB in biological media [11-12]. Previous 
publications have described methods for the analysis of BCQB in 
animals’ samples by LC-MS. However, the lower limit of quantitation 
(LLOQ) of the methods was too high (3 ng/ml and 0.05 ng/ml) and not 
applicable. BCQB is an anticholinergic agent used in rhinitis, COPD and 
asthma, and is administered nasally at a very low dosage (180 µg). 
Therefore a highly sensitive and selective determination method is 
required. An LC-MS method for the determination of BCQB in human 
plasma was reported [13], but was less sensitive for drug interactions 
study and required a long analytical run time. 
In order to perform BCQB plasma measurements in connection with 
a clinical trial, the goal was to establish an analytical method with 
both high sensitivity and high capacity due to the expected low 
concentration of BCQB. We, therefore, designed and validated an 
effective LC-MS/MS method for BCQB determination. Our method 
was successfully applied in a pharmacokinetic drug interaction 
study between BCQB and paroxetine, a strong inhibitor of CYP2D6, 
and fulfilled the high demands of a low measuring range and a time 
constraint schedule. 
MATERIALS AND METHODS 
Chemicals and reagents 
The reference standard of BCQB (>99.7% purity) and 1-ethyl-
bencycloquidium bromide (IS) (>99.9% purity) (fig. 1) were supplied 
by Beijing Shiqiao Biological and Pharmaceutical Co. Ltd. (Beijing, 
China). The weak cation-exchange solid-phase extraction (WCE-SPE) 
columns were purchased from Cleanert TM Angela Technologies 
(Beijing, China). Methanol and Acetonitrile were of HPLC grade and 
purchased from Merck KGaA (Darmstadt, Germany). Formic acid, 
acetic acid and ammonium acetate were of analytical grade and 
purchased from Nanjing Chemical Reagent Co., Ltd. (Nanjing, China). 
Distilled water was used throughout the experiment. 
 
 
Fig. 1: Chemical structure of BCQB (A) and IS (B) 
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LC–MS/MS instrumentation and conditions  
The liquid chromatography was done on an Agilent 1200 Series 
liquid chromatography (Agilent Technologies, Palo Alto, CA, USA), 
which included an Agilent 1200 binary pump (model G1312B), 
vacuum degasser (model G1322A), Agilent 1200 autosampler 
(model G1367C), temperature-controlled column compartment 
(model G1330B). The chromatographic separation was achieved on 
a Hedera ODS-2 C18 column (150 mm×2.1 mm i.d., 5 μm d. p, 
Hanbon Sci. and Tech) protected by a security guard C18 column (4 
mm × 2.0 mm i.d., 5μm d. p, Phenomenex, Torrance, CA, USA) with a 
mobile phase of acetonitrile-10 mmol/l ammonium acetate solution 
containing 0.2% acetic acid (33:67, v/v) at a flow rate of 550 μl/min. 
The column temperature and auto-sampler temperature were 
maintained at 39 °C and 15 °C, respectively. The injection volume 
was 10 μl. The LC system was coupled with an Agilent 6410B triple 
quadrupole mass spectrometry (Agilent Technologies, USA) 
equipped with an electrospray ionization source (model G1956B). 
The mass spectrometry was operated in positive ESI mode with the 
drying gas (N2) flow of 12 L/min, nebulizer pressure of 50 psi, 
drying gas temperature of 350 °C, the capillary voltage of 4.5kV. The 
fragmentation transitions for the multiple reaction monitoring 
(MRM) were m/z 330.2 → 142.0 for BCQB and m/z 344.2 → 156.1 for 
the IS (fig. 2). The fragmentor voltage value set for BCQB and the IS 
was 170V, and the collision energy was 40eV.  
 
 
Fig. 2: Positive product ion mass spectra of BCQB (A) and IS (B) 
 
Preparation of calibration standards and quality control sample 
Calibration standards and quality control (QC) samples were 
prepared from independently weighed stocks. Standard stock 
solutions of BCQB and IS were prepared in methanol to a 
concentration of 1.006 mg/ml and 1.010 mg/ml. The stock solution 
of BCQB was further serially diluted to yield working solutions at 
several concentration levels, 100.6, 48.29, 40.24, 32.19, 16.10, 4.829, 
4.024, 1.207, 0.4024, 0.2012, 0.1408 and 0.0804 ng/ml. The working 
solution of I. S was prepared at the concentration of 6.05 ng/ml by 
diluting the standard stock solution in methanol. All stock and 
working solutions were kept at-20 °C. Calibration standards and 
quality control samples were prepared by spiking blank plasma with 
the appropriate amount of working solutions. Calibration standards 
were of 2.01, 5.03, 10.06, 30.18, 100.6, 402.4, 804.8, 1207 pg/ml. QC 
samples were prepared at concentration levels of 3.52 pg/ml (Low), 
120.7 pg/ml (Middle) and 1006 pg/ml (High). 
Sample preparation 
In this study, gravity was used to elute the solvents from the SPE 
column. The conditioning step involved activating the cartridge (1 
ml) with 2 ml of methanol followed by 1 ml of H2O and then 
conditioning the cartridge with 2 ml of ammonium acetate buffer 
(25 mmol, pH 7.0). Aliquot of 1 ml plasma sample was transferred to 
a 2 ml capped tube, into which 30 µl of the I. S. solution (6.05 ng/ml) 
was spiked. The sample mixtures were vortexed for 30 s and 
centrifuged at 16,000 rpm for 5 min, and loaded onto the 
conditioned cartridge drop-wise. The lockstep involved treating the 
cartridge with 2 ml of ammonium acetate buffer (25 mmol, pH 7.0) 
to adjust the pH of the system to ensure that the ionization of the 
sorbent bed and its ion-exchange interactions with the analytes 
were enabled. The wash step utilized 2 ml of methanol to remove all 
unretained species from the sorbent bed. Elution was achieved by 
the addition of 2 ml of methanol containing 2% formic acid. No 
vacuum system was employed in the SPE process. All plasma 
samples, condition and elution solutions were allowed to pass 
through the SPE cartridges with the aid of gravity to ensure that 
there was enough time for the equilibrium of ion-exchange reactions 
in every SPE step.  
The eluted solution was transferred to a 10 ml glass tube and 
evaporated to dryness at 40 ◦C under a stream of nitrogen. The dried 
extract was then dissolved in 100 ml of the mobile phase. The 
reconstituted solution was transferred to an autosampler vial and an 
aliquot of 10 µl injected into the chromatographic system. 
Method validation 
The method was validated according to the FDA’s industrial 
guidance for the bioanalytical method validation [14]. The method 
was validated for selectivity, linearity, recovery, matrix effect (ME), 
precision, accuracy, and stability. Method sensitivity was determined 
by the limit of detection (LOD) and low limit of quantification 
(LLOQ) based on a signal-to-noise ratio of 3:1 and 7:1, respectively. 
Selectivity and matrix effect was assessed by comparing the 
chromatograms of six different batches of blank plasma obtained 
from six different sources with those of corresponding spiked 
plasma. Each blank sample was tested for no endogenous 
interferences. Extraction recovery in plasma matrix for BCQB was 
determined at the three levels of QC and calculated as the ratio of analyte 
peak area from extracted QC samples to that from extracted blank 
matrices spiked with BCQB standard solution. To assess carryover 
effects, blanks were injected immediately after the highest calibration 
standard (ULOQ), and the response of any interfering peak had to be less 
than 20% of the response of an LLOQ sample. All validation experiments 
were carried out at three QC levels (Low QC, Middle QC and High QC) for 
precision and accuracy assessment. The precisions and accuracies 
should be within±15% except for LLOQ level, which should be 
within±20%. Auto-sampler stability, benchtop stability, freeze-thaw 
stability, post preparative stability and long-term stability of the analyte 
were assessed. Samples were considered to be stable when their relative 
error (RE) was less than 15%. 
Pharmacokinetic study 
The proposed analytical method was applied to the study of 
pharmacokinetic drug interaction between BCQB and paroxetine. 
The clinical pharmacokinetic trial was performed in accordance with 
guidelines established by the Declaration of Helsinki. The Ethics 
Committee of the West China Hospital of Sichuan University 
approved the study protocol and written informed consent had been 
obtained from each participant. The design of the study was an 
open-label, single-dose, two periods, single sequence crossover 
study. Chinese healthy volunteers were administered nasally a single 
dose of 180 μg of BCQB alone on day 1. Blood samples for 
pharmacokinetic evaluation were collected at 0 (pre-dose), 2 min, 5 
min, 10 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 9 h, 12 h, 15 h, 24 h 
and 36 h after BCQB administration. After a 7 d wash-out period, 
subjects were administered 20 mg of paroxetine once a day from day 
8 to day 17 and 180 μg of BCQB were co-administered with 20 mg of 
paroxetine on day 18. Blood samples were collected as mentioned 
above. The plasma fractions were stored at −20◦C until analysis. An 
aliquot of 1 ml of thawed plasma samples was spiked with the IS and 
processed as mentioned in Section 2.4 above. Each analytical run 
was validated according to the FDA guidance for industry: 
Bioanalytical and method validation. 
RESULTS AND DISCUSSION 
Method development and optimization 
Chromatographic conditions, especially the composition of the 
mobile phase, were optimized to enhance the sensitivity and achieve 
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better separation from an endogenous matrix, as well as shorten the 
total run time. In this study, acetonitrile rather than methanol was 
chosen as organic eluent because it provided a higher mass 
spectrometric response and lower background noise. Acetonitrile 
had a strong eluting strength on endogenous compounds, eliminated 
matrix effect and shortened the total analytical run time to 7.5 min 
instead of 12 min in previous methods. The LLOQ and ULOQ were 
improved and the calibration range was extended (2–1200 pg/ml) 
to fit into the drug drugs interaction study without further dilution 
step. The mass spectrometry valve was diverted to waste from 5.5 
min to 7.5 min when impurities from endogenous compounds were 
eluting from the HPLC. 
Method validation 
Selectivity and carryover 
The selectivity of the method was determined by analyzing blank 
controls from six different individuals. There was no endogenous 
interference observed at the retention times of BCQB and the IS, 
which were 3.35 and 4.25, respectively. No carry-over peaks were 
observed at the retention times of BCQB and the IS in the 
chromatogram of blank plasma injected after the highest 
concentration (ULOQ) sample. Typical MRM chromatograms of 
blank plasma samples, blank plasma spiked with BCQB at LLOQ level 
and the internal standard, and a plasma sample from a healthy 
volunteer at 1h after dosing, respectively, are shown in fig. 3. 
Linearity, accuracy and precision 
The Calibration curves were linear over the concentration range of 
2–1200 pg/ml with a correlation coefficient r2>0.998. The typical 
equations of the calibration curves were f = 0.006380×C+0.01538, 
where f represents the peak area ratio of the analytes to the IS and C 
represents the concentration of the analytes. Validation samples of 
five replicates of the LLOQ and QC samples were prepared and 
analyzed in three separate analytical batches to evaluate the 
accuracy and intra-day and inter-day precision of the methods. 
Assay precision was calculated using the relative standard deviation 
(R. SD %) and performing a one-way analysis of variance (ANOVA). 
The precision (RSD) and accuracy (RE) for quantification of BCQB in 
human plasma are summarized in table 1. The results showed that 
both intra-day and inter-day values were all within the acceptable 
ranges. The method was accurate and precise. 
Matrix effect and recovery  
The matrix effects evaluated for the QC standards at three 
concentration levels ranged from 98.3% to 103.3% for BCQB, 
suggesting no ion suppression or enhancement from the plasma 
matrix to the analytes. The mean recoveries, mean (RSD), of analytes 
at three concentration levels (3.52, 120.7, and 1006 pg/ml) were 
88.2% (4.7%), 85.3% (7.0%) and 87.2% (2.8%) for BCQB, 
respectively. The Matrix effect and recovery of the IS were 104.0 % 
and 89.5% (3.0%), respectively. 
 
Fig. 3: Typical MRM chromatograms of BCQB and IS. Blank 
plasma sample (A), blank plasma sample spiked with the 
analytes at LLOQ and IS (B), and plasma sample from a healthy 
volunteer at 1h after dosing (C)
 
Table 1: Precision and accuracy data for the analysis of BCQB in human plasma (n =5) 
Analytes  Concentration level (pg/ml) RSD (%) RE (%)  
Added Measured  Intra-batch Inter-batch 
Low QC 3.520 3.652±0.3 8.2 5.0 3.8 
Middle QC 120.7 119.1±5.5 4.6 9.1 -1.3 
High QC 1006 997.1±45.1 4.5 6.2 -0.9 
 
Table 2: Stability of BCQB in human plasma under various storage conditions (n = 3) 
Storage conditions 10.06 pg/ml 1006 pg/ml 
mean±SD RE (%) mean±SD RE (%) 
Room temperature, 15 h 4.034±0.11 12.4 1012±25 -1.4 
Auto-sampler stability, 14h 3.733±0.57 4.0 983.1±29.7 -4.2 
Post-preparative stability, 48h 3.716±0.41 3.5 1030±21 0.4 
Three freeze/thaw cycles 3.852±0.25 7.4 1028±10 0.2 
Long term stability, 15 w 3.747±0.48 4.4 1076±14 4.9 
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Stability studies 
The stability results summarized in table 2 revealed that BCQB was 
stable in the plasma sample for 15 h at room temperature and after 
three freeze-thaw cycles of 48 h. The analytes in processed plasma 
samples were stable in the auto-sampler for 14h at 15 °C. The post-
preparative stability was accessed for 48h. The spiked plasma 
samples with BCQB stored at-20 °C for long-term stability were 
found stable for a minimum period of 15 w. 
Application 
The validated LC-MS/MS method was successfully applied to the 
pharmacokinetic drug interaction studies of BCQB in twenty-one 
healthy Chinese volunteers [15]. The pharmacokinetic results of 
BCQB alone and BCQB co-administered with paroxetine are 
presented in fig. 4. Absorption of BCQB after nasal administration 
was rapid with a median Tmax of 10 min in both groups. The plasma 
concentrations decreased in a biphasic manner with the mean t½ of 
approximately 10 to 11 h across the doses. The co-administration of 
paroxetine with BCQB decreased the elimination rate of BCQB and 
increased its plasma concentration at the terminal phase. The 
geometric mean AUC0-36 of BCQB was increased by approximately 
33% during concomitant administration with paroxetine. The mean 
Cmax and t1/2 data showed no statistically significant difference 
(p>0.05). The results showed large inter-individual variability in 
BCQB plasma concentration; this was shown by the mean Cmax data 
for both treatments 240.1±186.8 pg/ml and 247.3±235.9 pg/ml, 
respectively.  
 
 
Fig. 4: Mean plasma concentration-time profiles of BCQB after 
single-dose administration and co-administration with 
paroxetine in healthy Chinese subjects, respectively [15] 
 
CONCLUSION  
A new sensitive, accurate, selective, and simple LC-ESI-MS/MS 
method has been developed and validated for the quantitative 
determination of BCQB in human plasma. The LC-MS/MS method 
validated in this study was robust, reproducible, accurate, precise 
and reliable. The method was successfully applied for the 
pharmacokinetic drug interaction studies between BCQB and other 
drugs.  
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